Pfizer Newswire

Pfizer Newswire

Comprehensive Real-Time News Feed for Pfizer.

Results 1 - 20 of 4,295 in Pfizer

  1. Women Health Therapeutics Market : Emergence of Advanced Technologies ...Read the original story w/Photo

    9 hrs ago | SBWire

    ... AG, Amgen, Inc., Eli Lilly Company, Bayer AG, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novo Nordisk A/S, and Pfizer, Inc. About Transparency Market Research Transparency Market Research (TMR) is a global market intelligence company providing ...

    Comment?

  2. Testosterone Replacement Therapy Market Revenues Will Reach US$1.3 Bn Globally in 2024Read the original story w/Photo

    10 hrs ago | SBWire

    ... Allergan plc, Novartis AG, AbbVie, Inc., Endo Pharmaceuticals, Inc., Bayer AG, Eli Lilly and Company, Mylan N.V., and Pfizer, Inc. About Transparency Market Research Transparency Market Research (TMR) is a global market intelligence company ...

    Comment?

  3. Companies drafting emergency plans for Trump tweetsRead the original story w/Photo

    10 hrs ago | The Hill

    ... response on the stock market was dramatic. The nine largest pharmaceutical companies - including Johnson & Johnson, Pfizer and Eli Lilly- lost $24.6 billion on the stock market in 20 minutes, though those stocks eventually bounced back. Earlier this ...

    Comment?

  4. Baring Asset Management Ltd Has $3,220,000 Stake in Pfizer Inc.Read the original story w/Photo

    14 hrs ago | Daily Political

    BARING ASSET MANAGEMENT Ltd reduced its position in shares of Pfizer Inc. by 11.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 95,066 shares of the biopharmaceutical company's stock after selling 12,614 shares during the period.

    Comment?

  5. Health and Wellness Products Market to Make Great Impact in Near Future by 2026Read the original story w/Photo

    14 hrs ago | SBWire

    ... Some of the key players identified across the value chain of the global health & wellness products market include Pfizer Inc., PROVANT HEALTH SOLUTIONS INC., Nestle, The Kraft Heinz Company, Arbonne International, LLC, Buy Wellness, GSK, Walgreen ...

    Comment?

  6. FY2016 EPS Estimates for Pfizer Inc. Decreased by AnalystRead the original story w/Photo

    15 hrs ago | IntersportsWire

    Equities research analysts at Jefferies Group cut their FY2016 earnings estimates for Pfizer in a note issued to investors on Wednesday. Jefferies Group analyst J. Holford now anticipates that the firm will post earnings per share of $2.40 for the year, down from their previous forecast of $2.45.

    Comment?

  7. Human Growth Hormone Market 2021 Forecasts Analysis: Novartis AG,...Read the original story w/Photo

    16 hrs ago | SBWire

    ... as issues being faced by the market are discussed in detail in this report. The four major players: Novartis AG., Pfizer Inc., Eli Lilly and Company and Novo Nordisk A/S are being profiled along with their key financials and strategies for growth. ...

    Comment?

  8. Pfizer Inc. (PFE) Lowered to "Buy" at Vetr Inc.Read the original story w/Photo

    17 hrs ago | IntersportsWire

    ... analysts also recently issued reports about the company. Goldman Sachs Group Inc. set a $36.00 price target on Pfizer and gave the company a neutral rating in a report on Wednesday. Sanford C. Bernstein restated an outperform rating on shares of ...

    Comment?

  9. Pfizer's (PFE) "Hold" Rating Reaffirmed at Jefferies GroupRead the original story w/Photo

    18 hrs ago | IntersportsWire

    ... firms have also recently weighed in on PFE. Sanford C. Bernstein reaffirmed an "overweight" rating on shares of Pfizer in a research note on Wednesday, December 7th. Credit Suisse Group AG reaffirmed a "buy" rating and set a $38.00 target price on ...

    Comment?

  10. Reasons A Regeneron Pharmaceuticals Takeover Is UnlikelyRead the original story w/Photo

    18 hrs ago | Seeking Alpha

    Speculation of a potential Regeneron Pharmaceuticals takeover by big pharma companies has resurfaced as they still search for deals to boost revenues. Allergan and Pfizer would not be interested to acquire Regeneron since they are more focused on buying back shares and making small acquisitions.

    Comment?

  11. Milner Therapeutics Institute Release: Company Announces New...Read the original story

    Yesterday | BioSpace

    The Milner Therapeutics Institute today announces Pfizer Inc. as a partner to the Milner Therapeutics Consortium. Pfizer has agreed to join the Consortium, which enables the efficient transfer of materials between industry and academia and allocation of funds for partnering opportunities in Cambridge.

    Comment?

  12. Pfizer Inc. (PFE) Earns "Hold" Rating from Jefferies GroupRead the original story w/Photo

    19 hrs ago | AmericanBankingNews.com

    ... to detect a ~16% difference."" Several other equities analysts have also issued reports on the company. Vetr lowered Pfizer from a "strong-buy" rating to a "buy" rating and set a $35.83 price objective on the stock. in a report on Wednesday. Goldman ...

    Comment?

  13. Vetr Inc. Upgrades Pfizer, Inc. (PFE) to Strong-BuyRead the original story w/Photo

    20 hrs ago | IntersportsWire

    ... of other research reports. Jefferies Group restated a "hold" rating and set a $30.00 price objective on shares of Pfizer in a research note on Monday, December 19th. Sanford C. Bernstein restated an "outperform" rating on shares of Pfizer in a ...

    Comment?

  14. Visa: Dog Of The YearRead the original story w/Photo

    Yesterday | Seeking Alpha

    ... Nike (NYSE: NKE ) competed against the world , and the stock suffered from lousy sentiment for the Athleisure space. Pfizer (NYSE: PFE ) succumbed to political sentiment and low growth prospects. The broad market (NYSEARCA: SPY ) managed a rally to ...

    Comment?

  15. [Superrich] Korea's Richest 100 born in the year of chickenRead the original story w/Photo

    Yesterday | Korea Herald

    ... Celltrion started to sell the biosimilar for rheumatoid arthritis Remsima through the global pharmaceutical company, Pfizer Inc., last November. Also, Truxima, a biosimilar of anticancer drug for hematologic malignancy, has entered the exports ...

    Comment?

  16. Pfizer, Inc. (PFE) Stock Rating Lowered by Vetr Inc.Read the original story w/Photo

    Yesterday | AmericanBankingNews.com

    ... recently issued reports on the company. Argus reaffirmed a "buy" rating and set a $39.00 target price on shares of Pfizer in a research report on Tuesday, October 4th. Bank of America Corporation reaffirmed a "buy" rating and set a $36.00 target ...

    Comment?

  17. Price to defend investments at US Senate hearingRead the original story

    Yesterday | Mid-Day Mumbai

    ... invested in biotech firm Amgen Inc, insurer Aetna Inc and drugmakers Bristol-Myers Squibb Co, Eli Lilly & Co and Pfizer Inc, the Journal said, citing stock trade filings that Price made with Congress. Trump transition spokesman Phil Blando on ...

    Comment?

  18. How To Fix Executive Compensation And CEO Pay In Corporate AmericaRead the original story w/Photo

    Yesterday | Seeking Alpha

    ... in capital spending and R&D but spent $125 billion on share repurchases over the same period. Pharmaceutical giant Pfizer and 3M have shelled out $139 billion and $48 billion, respectively, on buybacks and dividends over the past decade. And ...

    Comment?

  19. Immune Checkpoint Inhibitors Market Global Industry Analysis 2016-...Read the original story w/Photo

    Yesterday | SBWire

    ... two immune checkpoint inhibitors and are expected to show positive results during the forecast period. For instance, Pfizer, Inc. in collaboration with the University of Pittsburgh is performing phase 2 clinical trials with Anti-CTLA4 monoclonal ...

    Comment?

  20. 5 Biotechs and the Drugs That May Put Them in DisfavorRead the original story

    Yesterday | BioSpace

    ... ve a big negative impact on the makers of the planet's most expensive drugs. Read on to find out why Eli Lilly & Co., Pfizer, Inc., Seattle Genetics, Ariad Pharmaceuticals, and Novelion Therapeutics could stand to lose out under Trump.

    Comment?